How does upfront CAR T‑cell therapy improve survival in multiple myeloma patients? ASH 2025: Key data HighlightsSeveral presentations at ASH 2025 focused on real-world outcomes following CAR T-cell therapy in multiple myeloma. Personalized Sequencing: Tailoring treatment to the IndividualThe data from ASH 2025 strongly supports a personalized approach to multiple myeloma treatment. CAR T-Cell Eligibility Assessment: Determining whether a patient is a suitable candidate for CAR T-cell therapy based on performance status, disease burden, and prior therapies. Real-World Example: A Case Study in De-EscalationA 62-year-old male diagnosed with high-risk multiple myeloma (del(17p)) received